Trinetra: Agile IT Modernization for Fortune 500 Companies
WEBEmpower your enterprise with Trinetra’s agile IT solutions designed for seamless business alignment, enhanced security, and scalability. Experience innovation that drives growth.
Celebrating Two Decades of Excellence: Trinetra Embarks on a
WEBMar 19, 2024 · As Trinetra Systems Inc. commemorates 20 years of unparalleled service and innovation in the IT sector, we're thrilled to announce a significant milestone in our journey: a comprehensive...
US FDA Grants Breakthrough Designation for Blood Test to Help …
WEBJan 2, 2023 · The TriNetra ™ -Glio liquid biopsy is intended to detect the cells released in the blood from the brain tumor; these cells are extremely rare and hard to detect. A prospective, blinded study by a...
FDA Grants Breakthrough Designation for Early-Stage Breast …
WEBNov 19, 2021 · TriNetra ™ is a Circulating Tumor Cell detection blood test which is able to identify early-stage Breast Cancer with high accuracy in women above the age of 40 years
TRINETRA LOGO INTRO - YouTube
WEBMar 29, 2023 · TRINETRA LOGO INTRO #logointro #logoanimation #korutla #trinetracreations
Trinetra
WEBSign In to get started. Email ID. Password
TriNetra™ - Clinically Validated
WEBTriNetra TM – Triumph is an advanced non-invasive liquid biopsy test which may help detect up to 50 different types of cancers at early stages through a simple blood draw. TriNetra TM – Triumph evaluates blood sample for presence of ‘Circulating Tumor Cells’ (CTCs), which are cancer cells that escape from the tumor and enter the blood ...
Non-Invasive Blood Test for Brain Cancer Acquires ... - Cancer …
WEBJan 4, 2023 · TriNetra ™-Glio is a non-invasive method of diagnostic stratification for patients with suspicious but non-specific neurocognitive symptoms. The test had previously received CE certification in the European Union and was available to …
TriNetra blood test secures FDA breakthrough status
WEBNov 22, 2021 · Datar Cancer Genetics has announced that its TriNetra blood test to detect early-stage breast cancer has secured breakthrough device designation from the US Food and Drug Administration (FDA). TriNetra uses a company-developed technology to identify circulating tumour cells (CTCs) that are specific to breast cancer.
FDA Grants Breakthrough Device Designation to Blood ... - Cancer …
WEBFeb 17, 2022 · Data have indicated that the TriNetra-Prostate blood test detects early-stage prostate cancer with more than 99% accuracy. The test requires 5 mL of blood in which prostate adenocarcinoma–specific circulating tumor cells can be detected.
- Some results have been removed